Anti-BCR-ABL

Catalog Number
AM903-10M
(100 tests - i6000)
Qty:
AM903-5M
(6 ml (RTU))
Qty:
AX903-50D
(50 tests - Xmatrx Elite/Ultra)
Qty:
AX903-YCD
(200 tests - Xmatrx Elite/Ultra)
Qty:
FB-903M
(5 slides - Xmatrx)
Out Of Stock
FG-903M
(5 slides - Manual)
Out Of Stock
MU903-1UC
(0.1 mL)
Out Of Stock
MU903-5UC
(0.5 ml (Conc.))
Qty:
MU903-UC
(1 ml (Conc.))
Qty:
$0.00
0
Translocation between chromosomes 9 and 22 lead to the formation of the Philadelphia chromosome which contain the BCR-ABL fusion gene found in most patients with Chronic Myeloid Leukemia (CML) and some patients with Acute Lymphoblastic leukemia (ALL) or Acute Myelogenous Leukemia (AML). The BCR-ABL oncoprotein possessing tyrosine kinase function is responsible for the pathogenesis of CML. Several domains of BCR-ABL protein coordinate, involve and contribute in the pathogenesis of CML. BCR-ABL aberrantly activates multiple signal pathways involving leukemic cell proliferation and survival. Besides GRB2 coupled RAS-MAPK and PI3K/AKT signal pathways, BCR-ABL also activates STAT5 and CRKL signal molecules.
Intended Use: ASR/RUO